Monte Rosa Therapeutics, Inc. Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Monte Rosa Therapeutics, Inc. (GLUE) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2026-03-17
- Monte Rosa Therapeutics, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Monte Rosa Therapeutics, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2024 was $4.47M, a 3368.99% increase from fiscal 2023.
- Monte Rosa Therapeutics, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2023 was $129.00K.
- Monte Rosa Therapeutics, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2022 was $0.00.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-17 |
| 2024-12-31 | $4.47M 10-K · filed 2026-03-17 |
| 2023-12-31 | $129.00K 10-K · filed 2025-03-20 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |